Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA131 in advanced hepatocellular carcinoma
NCT07282509Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, randomised, open-label trial of HA131 in hepatocellular carcinoma (HCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 3 years, Adverse Events at 3 years and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
HA131
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07282509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282509.